Abstract:Karuna Chavalertsakul, 1 Yuda Sutherasan, 1 Tananchai Petnak, 1 Kanin Thammavaranucupt, 2 Suppachok Kirdlarp, 2 Viboon Boonsarngsuk, 1 Somnuek Sungkanuparph 2 1 Division of Pulmonary and Pulmonary Critical Care Medicine, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 2 Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand Correspondence: Yuda Sutherasan, Division of Pulmonary and Pulmonary Critical Care Medicine, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, 270 Rama VI Road, Ratchathewi, Bangkok, 10400, Thailand, Tel +6622011619, Fax +6622011629 Ext 2, Email Background: Remdesivir treatment was associated with a reduced 28-day mortality and recovery time among patients hospitalized with severe COVID-19. Favipiravir is broadly used to treat COVID-19. However, various studies have had conflicting results on the efficacy of favipiravir for COVID-19. We hypothesized that remdesivir is more effective in clinical outcomes regarding the 29-day mortality rates, length of stay, and recovery rate than favipiravir in patients with moderate to severe COVID-19 pneumonia. Methods: We performed a retrospective cohort study that included adult hospitalized COVID-19 pneumonia patients with hypoxemia. Patients were classified into two groups according to the antiviral drugs. Age, oxygen saturation, fraction of inspired oxygen, and Charlson comorbidity index were used for propensity score matching. The primary objective was to determine whether the type of antiviral agent is associated with 29-day mortality. Other outcomes were the 15-day recovery rate and the length of intensive care unit or hospital stay. Results: A total of 249 patients with moderate to severe COVID-19 pneumonia were included. With an adjustment for propensity score-matched, there were 204 patients for further analysis (102 patients in each antiviral drug group). Remdesivir patients had higher Radiographic Assessment of Lung Edema (RALE) scores on Chest X-ray (14.32± 9.08 vs 11.34± 8.46; standardized mean difference =33.9%). The Charlson Comorbidity Index Scores were comparable. The prevalences of diabetes, obesity, hypertension, and non-HIV immunocompromised state were higher in the remdesivir group. Regarding the primary outcomes, after adjusting by diabetes, obesity, and RALE score, there was no difference in the 29-day mortality rate between both groups [26 patients (25.5%) in the remdesivir group vs 28 patients (27.5%) in the favipiravir group]. The Kaplan-Meier curve analysis at 29 days indicated no significant difference in cumulative survival rate. The two groups' adjusted hazard ratio was 0.72; 95% CI, 0.41 to 1.25, p =0.24. A Kaplan-Meier analysis on the 15-day cumulative survival rate observed a trend towards a higher survival rate in the remdesivir group (adjusted hazard ratio 0.41; 95% CI, 0.20 to 0.84; p= 0.02) The proportion of patients who recovered on day 15, the length of intensive care unit(ICU) stays, and the hospital stay were not different between remdesivir and favipiravir groups (62 patients (60.8%) vs 56 patients (54.9%), p=0.39; 11.48 ± 11.88 days vs 10.87 ± 9.31 days, p =0.69; and 16.64± 14.28 days vs 16.59 ± 11.31 days, p =0.98, respectively). Conclusion: In patients with moderate to severe COVID-19 pneumonia, Remdesivir did not demonstrate superior benefits over Favipiravir regarding 29-day mortality, 15-day recovery rates, or hospital and ICU stay lengths. However, further investigation into the 15-day cumulative survival rate revealed a trend towards improved survival in the Remdesivir group. Keywords: remdesivir, favipiravir, moderate to severe COVID-19 pneumonia The global pandemic Coronavirus disease 2019(COVID-19) was officially declared by the World Health Organization (WHO). The outbreak has profoundly impacted the healthcare and socioeconomic systems of many countries. 1 Studies on COVID-19 fatality rates among hospitalized patients have shown variations over time. The reports from 2020 to 2021 indicated mortality rates of around 17 to 50%. A study in 2023 stated that the global hospital mortality rate of COVID-19 among general patients was 16%, with variations observed across different geographic areas. 2 Several therapeutic strategies have been attempted, including antiviral drugs, corticosteroids, and immunomodulator therapy. 3 The rationale behind using antiviral agents in treating COVID-19 is inhibiting viral replication, reducing disease severity, and mitigating cytokine storms by dampening the exaggerated immune response. Early administr -Abstract Truncated-

Cardiac Adverse Events With Remdesivir in COVID-19 Infection

Cardiac Arrhythmia Related to Remdesivir in COVID-19

Remdesivir associated sinus bradycardia in patients with COVID-19: A prospective longitudinal study

Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database

Investigating the effects of remdesivir on corrected QT interval in patients with severe COVID-19 disease: a historical cohort study

ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential

Electrophysiological and sick sinus syndrome effects of Remdesivir challenge in guinea-pig hearts

Among Patients with COVID-19, should Remdesivir be Used for Treatment? A Systematic Review and Meta-analysis

Cardiac Adverse Events and Remdesivir in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19): A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial

[Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir]

Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS

Management of vulnerable patients hospitalized for COVID-19 with remdesivir: a retrospective comparative effectiveness study of mortality in US hospitals

Hepatic manifestations of COVID-19 and effect of remdesivir on liver function in patients with COVID-19 illness

Favipiravir-induced bradycardia: A case report

Remdesivir is associated with reduced mortality in patients hospitalized for COVID-19 not requiring supplemental oxygen

The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis

Remdesivir for the Treatment of COVID-19: A Narrative Review

Clinical outcomes and safety of remdesivir in hospitalized individuals with COVID-19, with or without severe renal impairment

Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data

Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care